Antiviral therapy for adenovirus infections

Antiviral Research

Volumn 71, Issue 2-3 SPEC. ISS., 2006, Pages 172-180

  Lenaerts, L ^a   Naesens, L ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Adenovirus; Antiviral; Cidofovir; Immunocompromised host; Immunotherapy; Ribavirin

Indexed keywords

2 AMINO 7 [(1,3 DIHYDROXY 2 PROPOXY)METHYL]PURINE; 2,4 DIAMINO 6 [3 HYDROXY 2 (PHOSPHONOMETHOXY)PROPOXY]PYRIMIDINE; 3' FLUOROTHYMIDINE; 6 AZACYTIDINE; 9 (3 HYDROXY 2 PHOSPHONOMETHOXYPROPYL)ADENINE; ACICLOVIR; ANTIVIRUS AGENT; ARGINYLGLYCYLASPARTIC ACID; CATECHIN; CATHELICIDIN; CIDOFOVIR; CYCLOPEPTIDE; DEFENSIN; GANCICLOVIR; GANCICLOVIR CYCLIC PHOSPHATE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; LACTOFERRIN; N CHLOROTAURINE; NUCLEOSIDE ANALOG; NUCLEOTIDE DERIVATIVE; POLYPEPTIDE ANTIBIOTIC AGENT; PROBENECID; PROTEINASE INHIBITOR; RIBAVIRIN; SIALIC ACID DERIVATIVE; STAVUDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIDARABINE; ZALCITABINE;

ANTIVIRAL ACTIVITY; CELL CULTURE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG DETERMINATION; DRUG SAFETY; DRUG TARGETING; ENCEPHALOMYELITIS; GRAFT VERSUS HOST REACTION; HUMAN; HYDRATION; IMMUNE DEFICIENCY; IMMUNOTHERAPY; KERATOCONJUNCTIVITIS; LEUKOCYTE TRANSFUSION; LIFE; NEPHROTOXICITY; NONHUMAN; PATIENT SATISFACTION; PRIORITY JOURNAL; PROTEIN TARGETING; RETINITIS; SHORT SURVEY; THREAT; VIRAL CONJUNCTIVITIS; VIRUS INFECTION;

ADENOVIRUS INFECTIONS, HUMAN; ADENOVIRUSES, HUMAN; ANIMALS; ANTIVIRAL AGENTS; CYTOSINE; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOCOMPROMISED HOST; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, SCID; PHOSPHONIC ACIDS; RIBAVIRIN;

ADENOVIRIDAE; ANIMALIA;

EID: 33747085476     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2006.04.007     Document Type: Short Survey

References (93)

1. Alexeeva I., Dyachenko N., Nosach L., Zhovnovataya V., Rybalko S., Lozitskaya R., Fedchuk A., Lozitsky V., Gridina T., Shalamay A., Palchikovskaja L., and Povnitsa O. 6-Azacytidine-compound with wide spectrum of antiviral activity. Nucleos. Nucleot. Nucleic Acids 20 (2001) 1147-1152
2. Allen L.B., Boswell K.H., Khwaja T.A., Meyer Jr. R.B., Sidwell R.W., Witkowski J.T., Christensen L.F., and Robins R.K. Synthesis and antiviral acticity of some phosphates of the broad-spectrum antiviral nucleoside, 1-beta-d-ribofuranosyl-1,2,4-triazole-3-carboxamide (ribavirin). J. Med. Chem. 21 (1978) 742-746
3. Arav-Boger R., Echavarria M., Forman M., Charache P., and Persaud D. Clearance of adenoviral hepatitis with ribavirin therapy in a pediatric liver transplant recipient. Pediatr. Infect. Dis. J. 19 (2000) 1097-1100
4. Arnberg N., Edlund K., Kidd A.H., and Wadell G. Adenovirus type 37 uses sialic acid as a cellular receptor. J. Virol. 74 (2000) 42-48
5. Arnberg N., Kidd A.H., Edlund K., Olfat F., and Wadell G. Initial interactions of subgenus D adenoviruses with A549 cellular receptors: sialic acid versus alpha(v) integrins. J. Virol. 74 (2000) 7691-7693
6. Arnold D., Di Biase A.M., Marchetti M., Pietrantoni A., Valenti P., Seganti L., and Superti F. Antiadenovirus activity of milk proteins: lactoferrin prevents viral infection. Antivir. Res. 53 (2002) 153-158
7. Baba M., Mori S., Shigeta S., and De Clercq E. Selective inhibitory effect of (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine and 2′-nor-cyclic GMP on adenovirus replication in vitro. Antimicrob. Agents Chemother. 31 (1987) 337-339
8. Baldwin A., Kingman H., Darville M., Foot A.B., Grier D., Cornish J.M., Goulden N., Oakhill A., Pamphilon D.H., Steward C.G., and Marks D.I. Outcome and clinical course of 100 patients with adenovirus infection following bone marrow transplantation. Bone Marrow Transplant. 26 (2000) 1333-1338
9. Bordigoni P., Carret A.S., Venard V., Witz F., and Le Faou A. Treatment of adenovirus infections in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin. Infect. Dis. 32 (2001) 1290-1297
10. Brandt C.D., Kim H.W., Vargosko A.J., Jeffries B.C., Arrobio J.O., Rindge B., Parrott R.H., and Chanock R.M. Infections in 18,000 infants and children in a controlled study of respiratory tract disease. I. Adenovirus pathogenicity in relation to serologic type and illness syndrome. Am. J. Epidemiol. 90 (1969) 484-500
11. Bruno B., Gooley T., Hackman R.C., Davis C., Corey L., and Boeckh M. Adenovirus infection in hematopoietic stem cell transplantation: effect of ganciclovir and impact on survival. Biol. Blood Marrow Transplant. 9 (2003) 341-352
12. Cao W., Baniecki M.L., McGrath W.J., Bao C., Deming C.B., Rade J.J., Lowenstein C.J., and Mangel W.F. Nitric oxide inhibits the adenovirus proteinase in vitro and viral infectivity in vivo. FASEB J. 17 (2003) 2345-2346
13. Cassano W.F. Intravenous ribavirin therapy for adenovirus cystitis after allogeneic bone marrow transplantation. Bone Marrow Transplant. 7 (1991) 247-248
14. Chakrabarti S., Mautner V., Osman H., Collingham K.E., Fegan C.D., Klapper P.E., Moss P.A., and Milligan D.W. Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. Blood 100 (2002) 1619-1627
15. Charles P.C., Guida J.D., Brosnan C.F., and Horwitz M.S. Mouse adenovirus type-1 replication is restricted to vascular endothelium in the CNS of susceptible strains of mice. Virology 245 (1998) 216-228
16. Chiang L.C., Cheng H.Y., Liu M.C., Chiang W., and Lin C.C. In vitro anti-herpes simplex viruses and anti-adenoviruses activity of twelve traditionally used medicinal plants in Taiwan. Biol. Pharm. Bull. 26 (2003) 1600-1604
17. Chuang Y.Y., Chiu C.H., Wong K.S., Huang J.G., Huang Y.C., Chang L.Y., and Lin T.Y. Severe adenovirus infection in children. J. Microbiol. Immunol. Infect. 36 (2003) 37-40
18. Crooks B.N., Taylor C.E., Turner A.J., Osman H.K., Abinun M., Flood T.J., and Cant A.J. Respiratory viral infections in primary immune deficiencies: significance and relevance to clinical outcome in a single BMT unit. Bone Marrow Transplant. 26 (2000) 1097-1102
19. Das A., Trousdale M.D., Ren S., and Lien E.J. Inhibition of herpes simplex virus type 1 and adenovirus type 5 by heterocyclic Schiff bases of aminohydroxyguanidine tosylate. Antivir. Res. 44 (1999) 201-208
20. De Clercq E. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clin. Microbiol. Rev. 16 (2003) 569-596
21. de Oliveira C.B., Stevenson D., LaBree L., McDonnell P.J., and Trousdale M.D. Evaluation of Cidofovir (HPMPC, GS-504) against adenovirus type 5 infection in vitro and in a New Zealand rabbit ocular model. Antivir. Res. 31 (1996) 165-172
22. Emovon O.E., Lin A., Howell D.N., Afzal F., Baillie M., Rogers J., Baliga P.K., Chavin K., Nickeleit V., Rajagapalan P.R., and Self S. Refractory adenovirus infection after simultaneous kidney-pancreas transplantation: successful treatment with intravenous ribavirin and pooled human intravenous immunoglobulin. Nephrol. Dial. Transplant. 18 (2003) 2436-2438
23. Garnett C.T., Erdman D., Xu W., and Gooding L.R. Prevalence and quantitation of species C adenovirus DNA in human mucosal lymphocytes. J. Virol. 76 (2002) 10608-10616
24. Ginsberg H.S., Moldawer L.L., Sehgal P.B., Redington M., Kilian P.L., Chanock R.M., and Prince G.A. A mouse model for investigating the molecular pathogenesis of adenovirus pneumonia. Proc. Natl. Acad. Sci. USA 88 (1991) 1651-1655
25. Gorczynska E., Turkiewicz D., Rybka K., Toporski J., Kalwak K., Dyla A., Szczyra Z., and Chybicka A. Incidence, clinical outcome, and management of virus-induced hemorrhagic cystitis in children and adolescents after allogeneic hematopoietic cell transplantation. Biol. Blood Marrow Transplant. 11 (2005) 797-804
26. Gordon Y.J., Araullo-Cruz T.P., Johnson Y.F., Romanowski E.G., and Kinchington P.R. Isolation of human adenovirus type 5 variants resistant to the antiviral cidofovir. Invest. Ophthalmol. Vis. Sci. 37 (1996) 2774-2778
27. Gordon Y.J., Huang L.C., Romanowski E.G., Yates K.A., Proske R.J., and McDermott A.M. Human cathelicidin (LL-37), a multifunctional peptide, is expressed by ocular surface epithelia and has potent antibacterial and antiviral activity. Curr. Eye Res. 30 (2005) 385-394
28. Gordon Y.J., Naesens L., De Clercq E., Maudgal P.C., and Veckeneer M. Treatment of adenoviral conjunctivitis with topical cidofovir. Cornea 15 (1996) 546
29. Gordon Y.J., Romanowski E., and Araullo-Cruz T. An ocular model of adenovirus type 5 infection in the NZ rabbit. Invest. Ophthalmol. Vis. Sci. 33 (1992) 574-580
30. Gordon Y.J., Romanowski E., Araullo-Cruz T., Seaberg L., Erzurum S., Tolman R., and De Clercq E. Inhibitory effect of (S)-HPMPC, (S)-HPMPA, and 2′-nor-cyclic GMP on clinical ocular adenoviral isolates is serotype-dependent in vitro. Antivir. Res. 16 (1991) 11-16
31. Gordon Y.J., Romanowski E.G., and Araullo-Cruz T. Topical HPMPC inhibits adenovirus type 5 in the New Zealand rabbit ocular replication model. Invest. Ophthalmol. Vis. Sci. 35 (1994) 4135-4143
32. Graci J.D., and Cameron C.E. Mechanisms of action of ribavirin against distinct viruses. Rev. Med. Virol. 16 (2006) 37-48
33. Guida J.D., Fejer G., Pirofski L.A., Brosnan C.F., and Horwitz M.S. Mouse adenovirus type 1 causes a fatal hemorrhagic encephalomyelitis in adult C57BL/6 but not BALB/c mice. J. Virol. 69 (1995) 7674-7681
34. Hale G.A., Heslop H.E., Krance R.A., Brenner M.A., Jayawardene D., Srivastava D.K., and Patrick C.C. Adenovirus infection after pediatric bone marrow transplantation. Bone Marrow Transplant. 23 (1999) 277-282
35. Hartline C.B., Gustin K.M., Wan W.B., Ciesla S.L., Beadle J.R., Hostetler K.Y., and Kern E.R. Ether lipid-ester prodrugs of acyclic nucleoside phosphonates: activity against adenovirus replication in vitro. J. Infect. Dis. 191 (2005) 396-399
36. Hillenkamp J., Reinhard T., Ross R.S., Bohringer D., Cartsburg O., Roggendorf M., De Clercq E., Godehardt E., and Sundmacher R. Topical treatment of acute adenoviral keratoconjunctivitis with 0.2% cidofovir and 1% cyclosporine: a controlled clinical pilot study. Arch. Ophthalmol. 119 (2001) 1487-1491
37. Hillenkamp J., Reinhard T., Ross R.S., Bohringer D., Cartsburg O., Roggendorf M., De Clercq E., Godehardt E., and Sundmacher R. The effects of cidofovir 1% with and without cyclosporin a 1% as a topical treatment of acute adenoviral keratoconjunctivitis: a controlled clinical pilot study. Ophthalmology 109 (2002) 845-850
38. Hippenmeyer P.J., Ruminski P.G., Rico J.G., Lu H.S., and Griggs D.W. Adenovirus inhibition by peptidomimetic integrin antagonists. Antivir. Res. 55 (2002) 169-178
39. Hoffman J.A., Shah A.J., Ross L.A., and Kapoor N. Adenoviral infections and a prospective trial of cidofovir in pediatric hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 7 (2001) 388-394
40. Holy A., Votruba I., Masojidkova M., Andrei G., Snoeck R., Naesens L., De Clercq E., and Balzarini J. 6-[2-(Phosphonomethoxy)alkoxy]pyrimidines with antiviral activity. J. Med. Chem. 45 (2002) 1918-1929
41. Horne W.S., Wiethoff C.M., Cui C., Wilcoxen K.M., Amorin M., Ghadiri M.R., and Nemerow G.R. Antiviral cyclic d,l-alpha-peptides: targeting a general biochemical pathway in virus infections. Bioorg. Med. Chem. 13 (2005) 5145-5153
42. Howard D.S., Phillips II G.L., Reece D.E., Munn R.K., Henslee-Downey J., Pittard M., Barker M., and Pomeroy C. Adenovirus infections in hematopoietic stem cell transplant recipients. Clin. Infect. Dis. 29 (1999) 1494-1501
43. Hromas R., Clark C., Blanke C., Tricot G., Cornetta K., Hedderman A., and Broun E.R. Failure of ribavirin to clear adenovirus infections in T cell-depleted allogeneic bone marrow transplantation. Bone Marrow Transplant. 14 (1994) 663-664
44. Kajon A.E., Gigliotti A.P., and Harrod K.S. Acute inflammatory response and remodeling of airway epithelium after subspecies B1 human adenovirus infection of the mouse lower respiratory tract. J. Med. Virol. 71 (2003) 233-244
45. Kampmann B., Cubitt D., Walls T., Naik P., Depala M., Samarasinghe S., Robson D., Hassan A., Rao K., Gaspar H., Davies G., Jones A., Cale C., Gilmour K., Real M., Foo M., Bennett-Rees N., Hewitt A., Amrolia P., and Veys P. Improved outcome for children with disseminated adenoviral infection following allogeneic stem cell transplantation. Br. J. Haematol. 130 (2005) 595-603
46. 3 against adenovirus in vitro. Antivir. Res. 52 (2001) 281-288
47. Kaneko H., Mori S., Suzuki O., Iida T., Shigeta S., Abe M., Ohno S., Aoki K., and Suzutani T. The cotton rat model for adenovirus ocular infection: antiviral activity of cidofovir. Antivir. Res. 61 (2004) 63-66
48. Kinchington P.R., Araullo-Cruz T., Vergnes J.P., Yates K., and Gordon Y.J. Sequence changes in the human adenovirus type 5 DNA polymerase associated with resistance to the broad spectrum antiviral cidofovir. Antivir. Res. 56 (2002) 73-84
49. Kinchington P.R., Romanowski E.G., and Jerold G.Y. Prospects for adenovirus antivirals. J. Antimicrob. Chemother. 55 (2005) 424-429
50. Kirsi J.J., North J.A., McKernan P.A., Murray B.K., Canonico P.G., Huggins J.W., Srivastava P.C., and Robins R.K. Broad-spectrum antiviral activity of 2-beta-d-ribofuranosylselenazole-4-carboxamide, a new antiviral agent. Antimicrob. Agents Chemother. 24 (1983) 353-361
51. Kodama E., Shigeta S., Suzuki T., and De Clercq E. Application of a gastric cancer cell line (MKN-28) for anti-adenovirus screening using the MTT method. Antivir. Res. 31 (1996) 159-164
52. Kojaoghlanian T., Flomenberg P., and Horwitz M.S. The impact of adenovirus infection on the immunocompromised host. Rev. Med. Virol. 13 (2003) 155-171
53. La Rosa A.M., Champlin R.E., Mirza N., Gajewski J., Giralt S., Rolston K.V., Raad I., Jacobson K., Kontoyiannis D., Elting L., and Whimbey E. Adenovirus infections in adult recipients of blood and marrow transplants. Clin. Infect. Dis. 32 (2001) 871-876
54. Lankester A.C., Heemskerk B., Claas E.C., Schilham M.W., Beersma M.F., Bredius R.G., van Tol M.J., and Kroes A.C. Effect of ribavirin on the plasma viral DNA load in patients with disseminating adenovirus infection. Clin. Infect. Dis. 38 (2004) 1521-1525
55. Leen A.M., and Rooney C.M. Adenovirus as an emerging pathogen in immunocompromised patients. Br. J. Haematol. 128 (2005) 135-144
56. Legrand F., Berrebi D., Houhou N., Freymuth F., Faye A., Duval M., Mougenot J.F., Peuchmaur M., and Vilmer E. Early diagnosis of adenovirus infection and treatment with cidofovir after bone marrow transplantation in children. Bone Marrow Transplant. 27 (2001) 621-626
57. Lenaerts L., Verbeken E., De Clercq E., and Naesens L. Mouse adenovirus type 1 infection in SCID mice: an experimental model for antiviral therapy of systemic adenovirus infections. Antimicrob. Agents Chemother. 49 (2005) 4689-4699
58. Ljungman P., Ribaud P., Eyrich M., Matthes-Martin S., Einsele H., Bleakley M., Machaczka M., Bierings M., Bosi A., Gratecos N., and Cordonnier C. Cidofovir for adenovirus infections after allogeneic hematopoietic stem cell transplantation: a survey by the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 31 (2003) 481-486
59. Mangel W.F., Baniecki M.L., and McGrath W.J. Specific interactions of the adenovirus proteinase with the viral DNA, an 11-amino-acid viral peptide, and the cellular protein actin. Cell. Mol. Life Sci. 60 (2003) 2347-2355
60. Mei Y.F., Lindman K., and Wadell G. Two closely related adenovirus genome types with kidney or respiratory tract tropism differ in their binding to epithelial cells of various origins. Virology 240 (1998) 254-266
61. Mentel R., Kinder M., Wegner U., Janta-Lipinski M., and Matthes E. Inhibitory activity of 3′-fluoro-2′ deoxythymidine and related nucleoside analogues against adenoviruses in vitro. Antivir. Res. 34 (1997) 113-119
62. Mentel R., Kurek S., Wegner U., Janta-Lipinski M., Gurtler L., and Matthes E. Inhibition of adenovirus DNA polymerase by modified nucleoside triphosphate analogs correlate with their antiviral effects on cellular level. Med. Microbiol. Immunol. (Berl) 189 (2000) 91-95
63. Mentel R., and Wegner U. Evaluation of the efficacy of 2′,3′-dideoxycytidine against adenovirus infection in a mouse pneumonia model. Antivir. Res. 47 (2000) 79-87
64. Miyamura K., Hamaguchi M., Taji H., Kanie T., Kohno A., Tanimoto M., Saito H., Kojima S., Matsuyama T., Kitaori K., Nagafuji K., Sato T., and Kodera Y. Successful ribavirin therapy for severe adenovirus hemorrhagic cystitis after allogeneic marrow transplant from close HLA donors rather than distant donors. Bone Marrow Transplant. 25 (2000) 545-548
65. Moore M.L., McKissic E.L., Brown C.C., Wilkinson J.E., and Spindler K.R. Fatal disseminated mouse adenovirus type 1 infection in mice lacking B cells or Bruton's tyrosine kinase. J. Virol. 78 (2004) 5584-5590
66. Morfin F., Dupuis-Girod S., Mundweiler S., Falcon D., Carrington D., Sedlacek P., Bierings M., Cetkovsky P., Kroes A.C., van Tol M.J., and Thouvenot D. In vitro susceptibility of adenovirus to antiviral drugs is species-dependent. Antivir. Ther. 10 (2005) 225-229
67. Mul Y.M., van Miltenburg R.T., De Clercq E., and van der Vliet P.C. Mechanism of inhibition of adenovirus DNA replication by the acyclic nucleoside triphosphate analogue (S)-HPMPApp: influence of the adenovirus DNA binding protein. Nucleic Acids Res. 17 (1989) 8917-8929
68. Muller W.J., Levin M.J., Shin Y.K., Robinson C., Quinones R., Malcolm J., Hild E., Gao D., and Giller R. Clinical and in vitro evaluation of cidofovir for treatment of adenovirus infection in pediatric hematopoietic stem cell transplant recipients. Clin. Infect. Dis. 41 (2005) 1812-1816
69. Munoz F.M., Piedra P.A., and Demmler G.J. Disseminated adenovirus disease in immunocompromised and immunocompetent children. Clin. Infect. Dis. 27 (1998) 1194-1200
70. Naesens L., Lenaerts L., Andrei G., Snoeck R., Van Beers D., Holy A., Balzarini J., and De Clercq E. Antiadenovirus activities of several classes of nucleoside and nucleotide analogues. Antimicrob. Agents Chemother. 49 (2005) 1010-1016
71. Nagafuji K., Aoki K., Henzan H., Kato K., Miyamoto T., Eto T., Nagatoshi Y., Ohba T., Obama K., Gondo H., and Harada M. Cidofovir for treating adenoviral hemorrhagic cystitis in hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 34 (2004) 909-914
72. Nagl M., Larcher C., and Gottardi W. Activity of N-chlorotaurine against herpes simplex- and adenoviruses. Antivir. Res. 38 (1998) 25-30
73. Nebbia G., Chawla A., Schutten M., Atkinson C., Raza M., Johnson M., and Geretti A. Adenovirus viraemia and dissemination unresponsive to antiviral therapy in advanced HIV-1 infection. AIDS 19 (2005) 1339-1340
74. Neher A., Nagl M., Prieskorn D., Mitchell A., Brown N., Schrott-Fischer A., and Miller J.M. Tolerability of N-chlorotaurine in the guinea pig middle ear: a pilot study using an improved application system. Ann. Otol. Rhinol. Laryngol. 113 (2004) 76-81
75. 7-substituted acyclic nucleoside analog 2-amino-7-(1,3-dihydroxy-2-propoxymethyl)purine, a potent inhibitor of herpesvirus replication. Mol. Pharmacol. 53 (1998) 157-165
76. Pang Y.P., Xu K., Kollmeyer T.M., Perola E., McGrath W.J., Green D.T., and Mangel W.F. Discovery of a new inhibitor lead of adenovirus proteinase: steps toward selective, irreversible inhibitors of cysteine proteinases. FEBS Lett. 502 (2001) 93-97
77. Quenelle D.C., Collins D.J., Wan W.B., Beadle J.R., Hostetler K.Y., and Kern E.R. Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir. Antimicrob. Agents Chemother. 48 (2004) 404-412
78. Romanowski E.G., Yates K.A., and Gordon Y.J. Antiviral prophylaxis with twice daily topical cidofovir protects against challenge in the adenovirus type 5/New Zealand rabbit ocular model. Antivir. Res. 52 (2001) 275-280
79. Schilham M.W., Claas E.C., van Zaane W., Heemskerk B., Vossen J.M., Lankester A.C., Toes R.E., Echavarria M., Kroes A.C., and van Tol M.J. High levels of adenovirus DNA in serum correlate with fatal outcome of adenovirus infection in children after allogeneic stem-cell transplantation. Clin. Infect. Dis. 35 (2002) 526-532
80. Segerman A., Atkinson J.P., Marttila M., Dennerquist V., Wadell G., and Arnberg N. Adenovirus type 11 uses CD46 as a cellular receptor. J. Virol. 77 (2003) 9183-9191
81. Sidwell R.W., Huffman J.H., Khare G.P., Allen L.B., Witkowski J.T., and Robins R.K. Broad-spectrum antiviral activity of virazole: 1-beta-d-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science 177 (1972) 705-706
82. Sircar S., Ruzindana-Umunyana A., Neugebauer W., and Weber J.M. Adenovirus endopeptidase and papain are inhibited by the same agents. Antivir. Res. 40 (1998) 45-51
83. Straussberg R., Harel L., Levy Y., and Amir J. A syndrome of transient encephalopathy associated with adenovirus infection. Pediatrics 107 (2001) E69
84. Teuchner B., Nagl M., Schidlbauer A., Ishiko H., Dragosits E., Ulmer H., Aoki K., Ohno S., Mizuki N., Gottardi W., and Larcher C. Tolerability and efficacy of N-chlorotaurine in epidemic keratoconjunctivitis-a double-blind, randomized, phase-2 clinical trial. J. Ocul. Pharmacol. Ther. 21 (2005) 157-165
85. Tsai J.C., Garlinghouse G., McDonnell P.J., and Trousdale M.D. An experimental animal model of adenovirus-induced ocular disease. The cotton rat. Arch. Ophthalmol. 110 (1992) 1167-1170
86. Uckun F.M., Pendergrass S., Qazi S., Samuel P., and Venkatachalam T.K. Phenyl phosphoramidate derivatives of stavudine as anti-HIV agents with potent and selective in-vitro antiviral activity against adenovirus. Eur. J. Med. Chem. 39 (2004) 225-234
87. van der Vliet P.C., van Bergen B.G., van Driel W., van Dam D., and Kwant M.M. Replication in vitro of adenovirus DNA. Adv. Exp. Med. Biol. 179 93-105 (1984) 93-105
88. van Tol M.J., Claas E.C., Heemskerk B., Veltrop-Duits L.A., de Brouwer C.S., van Vreeswijk T., Sombroek C.C., Kroes A.C., Beersma M.F., de Klerk E.P., Egeler R.M., Lankester A.C., and Schilham M.W. Adenovirus infection in children after allogeneic stem cell transplantation: diagnosis, treatment and immunity. Bone Marrow Transplant. 35 Suppl. 1 (2005) S73-S76
89. Walls T., Hawrami K., Ushiro-Lumb I., Shingadia D., Saha V., and Shankar A.G. Adenovirus infection after pediatric bone marrow transplantation: is treatment always necessary?. Clin. Infect. Dis. 40 (2005) 1244-1249
90. Weber J.M., Ruzindana-Umunyana A., Imbeault L., and Sircar S. Inhibition of adenovirus infection and adenain by green tea catechins. Antivir. Res. 58 (2003) 167-173
91. Wildner O., Hoffmann D., Jogler C., and Uberla K. Comparison of HSV-1 thymidine kinase-dependent and -independent inhibition of replication-competent adenoviral vectors by a panel of drugs. Cancer Gene Ther. 10 (2003) 791-802
92. Xiao J., Nataraja K., Rajala M.S., Astley R.A., Ramadan R.T., and Chodosh J. Vitronectin: a possible determinant of adenovirus type 19 tropism for human corneal epithelium. Am. J. Ophthalmol. 140 (2005) 363-369
93. Zarubaev V.V., Slita A.V., Krivitskaya V.Z., Sirotkin A.K., Kovalenko A.L., and Chatterjee N.K. Direct antiviral effect of cycloferon (10-carboxymethyl-9-acridanone) against adenovirus type 6 in vitro. Antivir. Res. 58 (2003) 131-137